Celldex Therapeutics (CLDX) Operating Leases (2019 - 2025)
Historic Operating Leases for Celldex Therapeutics (CLDX) over the last 7 years, with Q3 2025 value amounting to $1.1 million.
- Celldex Therapeutics' Operating Leases fell 3747.07% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 3747.07%. This contributed to the annual value of $2.4 million for FY2024, which is 15441.81% up from last year.
- As of Q3 2025, Celldex Therapeutics' Operating Leases stood at $1.1 million, which was down 3747.07% from $1.5 million recorded in Q2 2025.
- Celldex Therapeutics' 5-year Operating Leases high stood at $2.6 million for Q4 2022, and its period low was $470000.0 during Q1 2024.
- Moreover, its 5-year median value for Operating Leases was $1.7 million (2024), whereas its average is $1.6 million.
- In the last 5 years, Celldex Therapeutics' Operating Leases tumbled by 7821.05% in 2024 and then soared by 31042.55% in 2025.
- Quarter analysis of 5 years shows Celldex Therapeutics' Operating Leases stood at $1.3 million in 2021, then skyrocketed by 99.69% to $2.6 million in 2022, then tumbled by 64.14% to $928000.0 in 2023, then soared by 154.42% to $2.4 million in 2024, then plummeted by 54.76% to $1.1 million in 2025.
- Its Operating Leases stands at $1.1 million for Q3 2025, versus $1.5 million for Q2 2025 and $1.9 million for Q1 2025.